No black box warning on record for Loryna

As of the latest FDA labeling reviewed, Loryna (DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS) does not carry a black box warning. Standard warnings and precautions still apply — see the full Loryna medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Vascular risks : Stop drospirenone and ethinyl estradiol if a thrombotic event occurs. Stop at least 4 weeks before and through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding. ( 5.1 ) COCs containing DRSP may be associated with a higher risk of venous thromboembolism (VTE) than COCs containing levonorgestre

No black box warning on record for Loryna

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Vascular risks : Stop drospirenone and ethinyl estradiol if a thrombotic event occurs. Stop at least 4 weeks before and through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding. ( 5.1 ) COCs containing DRSP may be associated with a higher risk of venous thromboembolism (VTE) than COCs containing levonorgestre

Loryna Black Box Warning

No black box warning on record for Loryna

Other warnings & precautions

Loryna Black Box Warning

No black box warning on record for Loryna

Other warnings & precautions